Olema Pharmaceuticals Inc
NASDAQ:OLMA
Intrinsic Value
Olema Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of OLMA.
Olema Pharmaceuticals Inc's market capitalization is 540.6m USD.
OLMA stock price is 9.83 USD.
OLMA.
OLMA. Open DCF Valuation
OLMA. Open Relative Valuation
OLMA has upside potential of 157% compared to the average analyst price target.
Open Wall St Estimates
OLMA has negative Free Cash Flow for the last twelve months.
OLMA has negative Operating Income for the last twelve months.
OLMA has negative Net Income for the last twelve months.
OLMA's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -922% to -903%, and is approaching profitability.
OLMA's ROE (Return on Equity) has significantly decreased in the last 3 years from -12% to -43%, and is approaching profitability.
OLMA's ROE (Return on Equity) for the past 12 months is negative and is equal to -43%.
OLMA's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -903%.
OLMA has negative three-year average ROE (Return on Equity): -32%. The company is not efficient at transforming stockholders' equity into net income.
OLMA has negative three-year average ROIC (Return on Invested Capital): -1 184%. The company is not efficient at using invested capital to generate operating income.
OLMA's short-term assets (267m USD) exceed its short-term liabilties (22m USD).
OLMA's long-term assets (277m USD) exceed its long-term liabilties (23m USD).
OLMA's D/E (Debt to Equity) is very low and is equal to 0.
OLMA's Altman Z-Score is very high and is equal to 17.21.
Fundamental Analysis
Olema Pharmaceuticals Inc
Balance Sheet Decomposition
Olema Pharmaceuticals Inc
| Current Assets | 266.5m |
| Cash & Short-Term Investments | 261.8m |
| Receivables | 673k |
| Other Current Assets | 4m |
| Non-Current Assets | 10.4m |
| PP&E | 3.3m |
| Other Non-Current Assets | 7.2m |
| Current Liabilities | 21.6m |
| Accounts Payable | 2.7m |
| Accrued Liabilities | 18.9m |
| Other Current Liabilities | 73k |
| Non-Current Liabilities | 1.4m |
| Other Non-Current Liabilities | 1.4m |
Earnings Waterfall
Olema Pharmaceuticals Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-105m
USD
|
|
Operating Income
|
-105m
USD
|
|
Other Expenses
|
8.3m
USD
|
|
Net Income
|
-96.7m
USD
|
Free Cash Flow Analysis
Olema Pharmaceuticals Inc
OLMA Profitability Score
Profitability Due Diligence
Olema Pharmaceuticals Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Olema Pharmaceuticals Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
OLMA Solvency Score
Solvency Due Diligence
Olema Pharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Olema Pharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
OLMA Price Targets Summary
Olema Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
OLMA
is 25.25 USD
with a low forecast of 20.2 USD and a high forecast of 31.5 USD.
Ownership
OLMA Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
OLMA Price
Olema Pharmaceuticals Inc
| Average Annual Return | -52.71% |
| Standard Deviation of Annual Returns | 39.95% |
| Max Drawdown | -96% |
| Market Capitalization | 540.6m USD |
| Shares Outstanding | 55 914 700 |
| Percentage of Shares Shorted | 19.4% |
Company Profile
Olema Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Olema Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in San Francisco, California and currently employs 73 full-time employees. The company went IPO on 2020-11-19. The firm is focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). OP-1250 is an oral small molecule clinical-stage product candidate for the treatment of endocrine-driven cancers. The company is designed based on a structural understanding of the ER. OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase four and six (CDK4/6) demonstrated robust tumor shrinkage in several xenograft models, including a breast cancer brain metastasis model. The company is in the Phase I/ IIclinical trial, and in Phase I combination with palbociclib, in patients with metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
You don't have any saved screeners yet
